You might not think about it, but the time of day you get your cancer treatment could make a difference. Scientists have been looking into how our body's internal clock, called the circadian rhythm, affects how well cancer drugs work. One type of drug, called immune checkpoint inhibitors (ICIs), has been quite successful in treating advanced biliary tract cancers (BT...

Biliary tract cancers, like cholangiocarcinoma and gallbladder cancer, are growing more common worldwide, and most patients get diagnosed when the disease has already advanced, leading to a grim outlook. Recently, combining immune checkpoint inhibitors, such as durvalumab and pembrolizumab, with the standard chemotherapy (gemcitabine plus cisplatin) has shown promisi...

Immune-checkpoint inhibitors (ICIs) have emerged as a powerful tool in the fight against advanced squamous cell lung cancer (LUSC). These drugs offer a glimmer of hope for patients who haven't found success with other treatments. But it's not a one-size-fits-all solution—some patients don't respond well. Doctors are working hard to identify who might need additional ...

Immuno-oncology drugs, like immune checkpoint inhibitors (ICIs), have shown potential in treating various cancers. For advanced non-small cell lung cancer (NSCLC) patients with PD-L1 expression of 50% or higher, single-drug ICI therapy that targets PD-L1 is the standard treatment. But can machine learning (ML) algorithms do a better job at predicting how well these t...